Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel, cisplatin, and 5-FU induction for locally advanced HNSCC
NCT01566435Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2012
- Primary completion
- Oct 2013
- Countries
- 1
- Sponsor
- Washington University School of Medicine
- Modality
- Small Molecules
- Drugs
- paclitaxel
- Conditions
- head and neck squamous cell carcinoma (HNSCC)
01
Overview
Phase 2, open-label trial of paclitaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by Washington University School of Medicine. Started Aug 2012; status: completed.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Registry description
This phase II trial studies the safety and effectiveness of an induction chemotherapy (ACF) consisting of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel), cisplatin and fluorouracil followed by chemoradiation therapy in treating patients with stage III-IV squamous cell cancer of the head and neck. ACF may be an effective way to reduce or downgrade locally aggressive tumors, and improve the chance of eradication by chemoradiation.
Beyond the preview
Go deeper on NCT01566435.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01566435.